Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 2.655 USD 1.72%
Market Cap: 1.1B USD

Wall Street
Price Targets

IOVA Price Targets Summary
Iovance Biotherapeutics Inc

Wall Street analysts forecast IOVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IOVA is 8.517 USD with a low forecast of 1.515 USD and a high forecast of 17.85 USD.

Lowest
Price Target
1.515 USD
43% Downside
Average
Price Target
8.517 USD
221% Upside
Highest
Price Target
17.85 USD
572% Upside
Iovance Biotherapeutics Inc Competitors:
Price Targets
CVAC
CureVac NV
3% Upside
GNFT
Genfit SA
67% Upside
068270
Celltrion Inc
3% Upside
DVYSR
Devyser Diagnostics AB
56% Upside
CGON
CG Oncology Inc
74% Upside
OCC
Orthocell Ltd
26% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
4% Upside
300685
Amoy Diagnostics Co Ltd
36% Upside

Revenue
Forecast

Revenue Estimate
Iovance Biotherapeutics Inc

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 4 years is 50%.

N/A
Past Growth
50%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-71%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IOVA's stock price target?
Price Target
8.517 USD

According to Wall Street analysts, the average 1-year price target for IOVA is 8.517 USD with a low forecast of 1.515 USD and a high forecast of 17.85 USD.

What is Iovance Biotherapeutics Inc's Revenue forecast?
Projected CAGR
50%

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 4 years is 50%.

Back to Top